Pembrolizumab plus lenvatinib showed promising anti-tumour activity and manageable safety in patients with recurrent CCGC, including in patients with disease progression following previous treatment with anti-angiogenic therapy. These findings support further evaluation of this combination in randomised controlled trials.
[Articles] Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial
The Lancet Oncology | | Natalie Y L Ngoi, Jung-Yun Lee, Diana Lim, Yee Liang Thian, Yi Wan Lim, Jack J Chan, Wen Yee Chay, Zewen Zhang, Anil Gopinathan, Siew Eng Lim, Jeffrey Low, Joseph Ng, Pearl Tong, Yong-Jae Lee, Junsik Park, Jae-Weon Kim, Tuan Zea Tan, Junxian Zhu, Bee Choo Tai, Chel Hun Choi, Byoung-Gie Kim, David S P Tan
Topics: cervical-cancer, immunotherapy, clinical-trials, research